To determine whether combined inhibition of the Notch and JAK/STAT pathways could mimic the effects of HepLPCs, HCC cells were treated with 10 μM DAPT and 10 μM ruxolitinib (Ruxo) to inhibit the Notch1 and STAT3 signaling pathways, respectively. The gene discussed is SOAT1; the disease is hepatocellular carcinoma.